StockData
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc. (ELOX) stock

ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$12.75−0.40 (-3.04%)

Close on Nov 16, 2026Market cap $86.56MP/E –Yield –

Eloxx Pharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Eloxx Pharmaceuticals's enterprise value was -$9.45M on Nov 11, 2026, against $6.41M a year earlier. Over the last 5 years it ranged from -$9.45M to $633.11M, with a median of $27.83M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$9.45M-247.4%
2025Dec 31, 2025$6.41M+137.6%
2024Dec 31, 2024$2.70M-90.8%
2023Dec 29, 2023$29.26M-6.2%
2022Dec 30, 2022$31.21M-95.1%
2021Dec 31, 2021$633.11M-63.6%
2020Dec 31, 2020$1.74B-45.4%
2019Dec 31, 2019$3.19B-30.5%
2018Dec 31, 2018$4.58B+154.3%
2017Dec 29, 2017$1.80B–

More Eloxx Pharmaceuticals figures

See a number that looks wrong?